Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af Aticaprant hos voksne og ældre deltagere med svær depressiv lidelse (MDD) (VENTURA-LT)

14. september 2026 opdateret af: Janssen Research & Development, LLC

En åben-label, langsigtet undersøgelse af sikkerhed og effektivitet af Aticaprant som supplerende terapi hos voksne og ældre deltagere med svær depressiv lidelse (MDD)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

871

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Buenos Aires, Argentina, C1181ACH
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, 1900
        • INSA Instituto de Neurociencias San Agustín
      • Buenos Aires, Argentina, C1061AAS
        • CIPREC
      • Buenos Aires, Argentina, C1013AAB
        • STAT Research S A
      • Buenos Aires, Argentina, C1133AAH
        • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
      • Ciudad Autonoma Buenos Aires, Argentina, 1058 AAJ
        • CENydET - Centro Neurobiologico y de Stress Traumatico
      • Córdoba, Argentina, 5000FJF
        • CEN Consultorios Especializados en Neurociencias
      • Córdoba, Argentina, 5000
        • Fundacion Lennox
      • Córdoba, Argentina, 5000
        • Instituto Medico DAMIC
      • Córdoba, Argentina, X5006IKK
        • Centro Medico Luquez
      • La Plata, Argentina, Thanks
        • Clinica Privada de Salud Mental Santa Teresa de Ávila
      • La Plata, Argentina, 1902
        • CENPIA
      • Mendoza, Argentina, M5502AHV
        • Resolution
      • Rosario, Argentina, 2000
        • C I A P Centro de investigacion y Asistencia en Psiquiatria
      • Rosario, Argentina, S2000DEJ
        • Instituto Medico de La Fundacion Estudios Clinicos
      • San Miguel de Tucumán, Argentina, 4000
        • Clinica Mayo de UMCB
      • Santiago del Estero, Argentina, 4200
        • Clinica El Jardin
      • Frankston, Australien, 3199
        • Peninsula Therapeutic & Research Group
      • Melbourne, Australien, 3004
        • The Alfred Hospital
      • Melbourne, Australien, 3004
        • Albert Road Clinic
      • Alken, Belgien, 3570
        • Anima
      • Brussels, Belgien, 1020
        • C.H.U. Brugmann
      • Duffel, Belgien, 2570
        • Pz Duffel
      • Sint-Niklaas, Belgien, 9100
        • Vitaz
      • Curitiba, Brasilien, 80240-280
        • Trial Tech Tecnologia em Pesquisas com Medicamentos
      • Fortaleza, Brasilien, 60430-380
        • Universidade Federal do Ceara Hospital Universitario Walter Cantidio
      • Goiânia, Brasilien, 74093 040
        • Instituto Goiano de Neuropsiquiatria
      • Porto Alegre, Brasilien, 90035-001
        • Associacao Hospitalar Moinhos de Vento
      • Porto Alegre, Brasilien, 90430001
        • NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
      • Rio de Janeiro, Brasilien, 22270 060
        • Ruschel Medicina e Pesquisa Clínica Ltda
      • São Bernardo, Brasilien, 09715-090
        • CEMEC - Centro Multidisciplinar de Estudos Clínicos
      • São José do Rio Preto, Brasilien, 15090 000
        • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
      • São Paulo, Brasilien, 01228-000
        • CPQuali Pesquisa Clinica LTDA ME
      • São Paulo, Brasilien, 05003 020
        • BR Trials
      • Cherven Bryag, Bulgarien, 5980
        • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
      • Plovdiv, Bulgarien, 4004
        • Medical Center Mentalcare OOD
      • Plovdiv, Bulgarien, 4002
        • Ambulatory Group practice for specialized help in psychiary Philipopolis ODD
      • Rousse, Bulgarien, 7003
        • Mental Health Center - Rousse
      • Sofia, Bulgarien, 1510
        • Medical Center Hera EOOD
      • Sofia, Bulgarien, 1202
        • MHC - Sofia, EOOD
      • Sofia, Bulgarien, 1408
        • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
      • Sofia, Bulgarien, 1680
        • Medical Center Intermedica, OOD
      • Sofia, Bulgarien, 1113
        • Medical Center St. Naum
      • Varna, Bulgarien, 9020
        • Diagnostic Consulting Center Mladost - M Varna
      • Veliko Tarnovo, Bulgarien, 5000
        • Mental Health Center - Veliko Tarnovo EOOD
    • Quebec
      • Sherbrooke, Quebec, Canada, J1L 0H8
        • DIEX Recherche Sherbrooke Inc
      • London, Det Forenede Kongerige, SE5 8AF
        • Institute of Psychiatry
      • Southampton, Det Forenede Kongerige, SO30 3JB
        • Moorgreen Hospital
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • University of Alabama at Birmingham - The Kirklin Clinic
    • Arizona
      • Tucson, Arizona, Forenede Stater, 85721
        • University of Arizona
      • Tucson, Arizona, Forenede Stater, 85712
        • SW Biomedical Research LLC
    • California
      • Anaheim, California, Forenede Stater, 92805
        • Advanced Research Center Inc
      • Culver City, California, Forenede Stater, 90230
        • Proscience Research Group
      • Glendale, California, Forenede Stater, 91206
        • Behavioral Research Specialists LLC
      • Lafayette, California, Forenede Stater, 94549
        • Sunwise Clinical Research
      • Long Beach, California, Forenede Stater, 90807
        • Asclepes Research
      • Oceanside, California, Forenede Stater, 92056
        • Excell Research Inc
      • Orange, California, Forenede Stater, 92868
        • Pacific Neuropsychiatric Specialists
      • Rancho Cucamonga, California, Forenede Stater, 91730
        • Prospective Research Innovations Inc
      • San Diego, California, Forenede Stater, 92103
        • University of California San Diego Medical Center
      • Santa Ana, California, Forenede Stater, 92705
        • Syrentis Clinical Research
      • Santee, California, Forenede Stater, 92071
        • CMB Clinical Trials
      • Sherman Oaks, California, Forenede Stater, 91403
        • California Neuroscience Research
      • Temecula, California, Forenede Stater, 92591
        • Viking Clinical Research Ltd
      • Upland, California, Forenede Stater, 91786
        • Pacific Clinical Research Medical Group
      • West Covina, California, Forenede Stater, 91790
        • Next Level Clinical Trials, LLC
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80910
        • MCB Clinical Research Centers LLC
    • Connecticut
      • Farmington, Connecticut, Forenede Stater, 06030
        • University of Connecticut Health Center
    • Florida
      • Clearwater, Florida, Forenede Stater, 33756
        • Innovative Research of West Florida, Incorporated
      • Coral Springs, Florida, Forenede Stater, 33067
        • CNS Clinical Research Group
      • Fort Myers, Florida, Forenede Stater, 33912
        • Gulfcoast Medical Research Center
      • Gainesville, Florida, Forenede Stater, 32607
        • Sarkis Clinical Trials
      • Hialeah, Florida, Forenede Stater, 33016
        • Galiz Research
      • Hialeah, Florida, Forenede Stater, 33012
        • New Life Medical Research Center, Inc.
      • Hialeah, Florida, Forenede Stater, 33013
        • Amedica Research Institute Inc
      • Maitland, Florida, Forenede Stater, 32751
        • Vertex Clinical Research
      • Miami, Florida, Forenede Stater, 33126
        • Pharmax Research Clinic Inc
      • Miami, Florida, Forenede Stater, 33175
        • Ezy Medical Research
      • Miami, Florida, Forenede Stater, 33174
        • Florida Research Center Inc.
      • Miami, Florida, Forenede Stater, 33144
        • A Plus Research
      • Miami, Florida, Forenede Stater, 33185
        • Felicidad Medical Research
      • Miami, Florida, Forenede Stater, 33122
        • Vital Care Research
      • Miami, Florida, Forenede Stater, 33126
        • LCC Medical Research Institute Inc
      • Miami, Florida, Forenede Stater, 33125
        • Global Medical Institutes 1
      • Miami Gardens, Florida, Forenede Stater, 33014
        • Meridian International Research
      • Miami Lakes, Florida, Forenede Stater, 33016
        • University of Miami
      • North Bay Village, Florida, Forenede Stater, 33141
        • Bravo Health Care Center
      • Ocoee, Florida, Forenede Stater, 34761
        • K2 Medical Research
      • Orange City, Florida, Forenede Stater, 32763
        • Medical Research Group of Central Florida
      • Orlando, Florida, Forenede Stater, 32803
        • APG Research LLC
      • Orlando, Florida, Forenede Stater, 32803
        • Combined Research Orlando
      • Pompano Beach, Florida, Forenede Stater, 33064
        • Quantum Laboratories
      • Port Saint Lucie, Florida, Forenede Stater, 34952
        • CDC Research Institute LLC
      • Tampa, Florida, Forenede Stater, 33613
        • USF, Department of Psychiatry and Behavioral Neurosciences
    • Illinois
      • Berwyn, Illinois, Forenede Stater, 60402
        • Research Network America
      • Chicago, Illinois, Forenede Stater, 60634
        • Chicago Research Center
      • Elgin, Illinois, Forenede Stater, 60123
        • Revive Research Institute
      • Skokie, Illinois, Forenede Stater, 60076
        • Psychiatric Medicine Associates LLC
    • Louisiana
      • Marrero, Louisiana, Forenede Stater, 70072
        • Tandem Clinical Research
      • Monroe, Louisiana, Forenede Stater, 71203
        • Clinical Trials of America
    • Maryland
      • Gaithersburg, Maryland, Forenede Stater, 20877
        • CBH Health
    • Massachusetts
      • Methuen, Massachusetts, Forenede Stater, 01844
        • ActivMed Practices and Research
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48105
        • Michigan Clinical Research Institute
    • Missouri
      • O'Fallon, Missouri, Forenede Stater, 63368
        • Psychiatric Care and Research Center (PCRC)
      • Saint Charles, Missouri, Forenede Stater, 63304
        • Midwest Research Group
    • New York
      • Buffalo, New York, Forenede Stater, 14215
        • Erie County Medical Center
      • Mount Kisco, New York, Forenede Stater, 10549
        • Bioscience Research LLC
      • New York, New York, Forenede Stater, 10036
        • Manhattan Behavioral Medicine
      • New York, New York, Forenede Stater, 10168
        • Fieve Clinical Research Inc
      • Rochester, New York, Forenede Stater, 14618 1609
        • Finger Lakes Clinical Research
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center PRIME
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28211
        • New Hope Clinical Research
      • Monroe, North Carolina, Forenede Stater, 28112
        • Monroe Biomedical Research
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
      • Cincinnati, Ohio, Forenede Stater, 45215
        • Patient Priority Clinical Sites LLC
      • Columbus, Ohio, Forenede Stater, 43221
        • Wexner Medical Center at the Ohio State University
      • Dayton, Ohio, Forenede Stater, 45417
        • Midwest Clinical Research Center
      • Garfield Heights, Ohio, Forenede Stater, 44125
        • Charak Center for Health and Wellness
    • Oklahoma
      • Edmond, Oklahoma, Forenede Stater, 73013
        • Conrad Clinical Research
      • Oklahoma City, Oklahoma, Forenede Stater, 73112
        • Sooner Clinical Research
      • Oklahoma City, Oklahoma, Forenede Stater, 73118
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18103
        • Lehigh Center for Clinical Research LLC
      • Media, Pennsylvania, Forenede Stater, 19063
        • Suburban Research Associates
      • Moosic, Pennsylvania, Forenede Stater, 18507
        • Global Medical Institutes
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • University of Pennsylvania - Perelman School of Medicine
    • Texas
      • Austin, Texas, Forenede Stater, 78737
        • Austin Clinical Trial Partners
      • Bellaire, Texas, Forenede Stater, 77401
        • West Houston Clinical Research Service
      • Dallas, Texas, Forenede Stater, 75235-9119
        • UT Southwestern Medical Center
      • Fort Worth, Texas, Forenede Stater, 76104
        • North Texas Clinical Trials
      • Houston, Texas, Forenede Stater, 77074
        • Clinical Trial Network - Houston
      • Katy, Texas, Forenede Stater, 77494
        • R and H Clinical Research
    • Utah
      • Clinton, Utah, Forenede Stater, 84015
        • Alpine Research Organization
      • Murray, Utah, Forenede Stater, 84107
        • Cedar Psychiatry
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22908
        • University of Virginia
    • Washington
      • Bellevue, Washington, Forenede Stater, 98007
        • Northwest Clinical Research Center
      • Bohars, Frankrig, 29820
        • CHU de Brest - Hopital de la Cavale Blanche
      • Clermont-Ferrand, Frankrig, 63000
        • CHU Clermont-Ferrand - Hopital Gabriel Montpied
      • Douai, Frankrig, 59500
        • Cabinet Medical des Drs Prizac-Desbonnet Scottez
      • Nantes, Frankrig, 44093
        • CHU de Nantes hotel Dieu
      • Paris, Frankrig, 75674
        • Hopital Sainte Anne
      • Tours, Frankrig, 37044
        • CHRU de Tours Clinique Psychiatrique Universitaire
      • Bergamo, Italien, 24127
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
      • Catanzaro, Italien, 88100
        • Azienda Ospedaliero Universitaria Mater Domini
      • Lecce, Italien, 73100
        • AUSL LE di Lecce
      • Milan, Italien
        • Ospedale San Raffaele
      • Milan, Italien, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, Italien, 20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Siena, Italien, 53100
        • Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
      • Baoding, Kina, 071000
        • Hebei Mental Health Center
      • Beijing, Kina, 100191
        • Peking University Sixth Hospital
      • Beijing, Kina, 100088
        • Beijing Anding Hospital of Capital Medical University
      • Beijing, Kina, 102208
        • Beijing Huilongguan Hospital
      • Changsha, Kina, 410011
        • The second Xiangya Hospital of Central South University
      • Chengdu, Kina, 610041
        • West China Hospital Sichuan University
      • Guangzhou, Kina, 510060
        • Guangdong Provincial People's Hospital
      • Huzhou, Kina, 313000
        • Huzhou third people's Hospital
      • Shanghai, Kina, 200030
        • Shanghai Mental Health Center
      • Shanghai, Kina, 200065
        • Tongji Hospital of Tongji University
      • Shijiazhuang, Kina, 050031
        • The First Hospital of Hebei Medical University
      • Suzhou, Kina, 215003
        • Suzhou Guangji Hospital
      • Tianjin, Kina, 300222
        • Tianjin Anding Hospital
      • Wuhan, Kina, 430022
        • Wuhan Mental Health Center
      • Wuhu, Kina, 242407
        • Wuhu Hospital of Beijing Anding hospital
      • Xi'an, Kina, 710061
        • XiAn Mental Healthcare Center
      • Zhengzhou, Kina, 450052
        • The First Affiliated Hospital of Zhengzhou University
      • Bełchatów, Polen, 97-400
        • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
      • Bialystok, Polen, 15-404
        • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
      • Bydgoszcz, Polen, 85 794
        • Clinsante Osrodek Badan Klinicznych
      • Gdansk, Polen, 80 546
        • Centrum Badan Klinicznych PI House sp z o o
      • Katowice, Polen, 40568
        • Centrum Medyczne Care Clinic Katowice
      • Lodz, Polen, 90-009
        • Specjalistyczna Indywidualna Praktyka Lekarska
      • Lodz, Polen, 92-215
        • SPZOZ Uniwersytecki Szpi.Klin. nr 4 UM w Lodzi
      • Poznan, Polen, 60-744
        • Filip Rybakowski Specjalistyczna Praktyka Lekarska
      • Poznan, Polen, 61-360
        • Osrodek Badan Klinicznych CROMED
      • Suchy Las, Polen, 62-002
        • Indywidualna Specjalistyczna Praktyka Lekarska Agnieszka Remlinger Molenda
      • Torun, Polen, 87 100
        • Specjalistyczny Gabinet Psychiatryczny Kowalkowski Gerard
      • Braga, Portugal, 4710-243
        • Hospital de Braga
      • Lisbon, Portugal, 1350 179
        • Hospital CUF Inf. Santo
      • Lisbon, Portugal, 1400 038
        • Fund. Champalimaud
      • Banská Bystrica, Slovakiet, 97401
        • Psychomed-Svatosavsky, s.r.o.
      • Bojnice, Slovakiet, 97201
        • Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
      • Bratislava, Slovakiet, 82007
        • Psychiatricka Ambulancia Mentum S.R.O.
      • Košice, Slovakiet, 040 11
        • Epamed sro
      • Košice, Slovakiet, 04190
        • Univerzitna nemocnica L. Pasteura Kosice
      • Liptovský Mikuláš, Slovakiet, 03123
        • Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
      • Rimavská Sobota, Slovakiet, 97901
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Vranov nad Topľou, Slovakiet, 09301
        • Crystal Comfort s.r.o.
      • Barcelona, Spanien, 08025
        • Institucion Hosp Hestia Palau
      • Barcelona, Spanien, 08036
        • Hosp Clinic de Barcelona
      • Barcelona, Spanien, 08035
        • Hosp Univ Vall D Hebron
      • Madrid, Spanien, 28046
        • Hosp. Univ. La Paz
      • Málaga, Spanien, 29009
        • Hosp Regional Univ de Malaga
      • Palma de Mallorca, Spanien, 07120
        • Hosp. Univ. Son Espases
      • Ponferrada, Spanien, 24404
        • Hosp. El Bierzo
      • Sabadell, Spanien, 08208
        • Corporacio Sanitari Parc Tauli
      • Vigo, Spanien, 36312
        • Hosp. Alvaro Cunqueiro
      • Vitoria-Gasteiz, Spanien, 01006
        • Hosp. Psiquiatrico Alava
      • Gothenburg, Sverige, 416 85
        • Sahlgrenska Universitetssjukhuset
      • Lund, Sverige, 22222
        • ProbarE i Lund AB
      • Stockholm, Sverige, 113 29
        • ProbarE i Stockholm AB
      • Stockholm, Sverige, 113 61
        • Studieenheten Akademiskt Specialistcentrum Stockholm
      • Cape Town, Sydafrika, 7530
        • Cape Town Clinical Research Centre
      • Pretoria, Sydafrika, 181
        • Gert Bosch Pretoria South Africa
      • Strand, Sydafrika, 7140
        • Somerset West Clinical Research Unit
      • Bucheon-si, Sydkorea, 420-717
        • The Catholic University Of Korea St Mary'S Hospital
      • Busan, Sydkorea, 612-030
        • Inje University Haeundae Paik Hospital
      • Gyeonggi-do, Sydkorea, 15355
        • Korea University Ansan Hospital
      • Seoul, Sydkorea, 05505
        • Asan Medical Center
      • Seoul, Sydkorea, 06351
        • Samsung Medical Center
      • Seoul, Sydkorea, 02447
        • Kyung Hee University Medical Center
      • Seoul, Sydkorea, 3080
        • Seoul National University Hospital
      • Seoul, Sydkorea, 02841
        • Korea University Anam Hospital
      • Seoul, Sydkorea, 07345
        • The Catholic University of Korea Yeouido St. Mary's Hospital
      • Taichung, Taiwan, 40447
        • China Medical University Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taipei, Taiwan, 110
        • Taipei Medical University
      • Taipei, Taiwan, 112
        • Cheng Hsin General Hospital
      • Brno, Tjekkiet, 61500
        • Psychiatricka ambulance, MUDr. Marta Holanova
      • Klecany, Tjekkiet, 25067
        • Narodni ustav dusevniho zdravi
      • Kutná Hora, Tjekkiet, 284 01
        • Neuroterapie KH S R O
      • Pilsen, Tjekkiet, 301 00
        • A Shine S R O
      • Prague, Tjekkiet, 16000
        • Medical Services Prague S R O
      • Prague, Tjekkiet, 100 00
        • Clintrial s r o
      • Prague, Tjekkiet, 15000
        • Praglandia s r o
      • Prague, Tjekkiet, 160 00
        • NeuropsychiatrieHK, s.r.o.
      • Prague, Tjekkiet, 10000
        • AD71 s.r.o.
      • Prague, Tjekkiet, 186 00
        • Institut Neuropsychiatricke pece
      • Ústí nad Labem, Tjekkiet, 400 01
        • Psychiatricka ordinace
      • Budapest, Ungarn, 1083
        • Semmelweis Egyetem
      • Budapest, Ungarn, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Gyöngyös, Ungarn, 3200
        • Bugat Pal Korhaz
      • Kalocsa, Ungarn, 6300
        • Dr Mathe es Tarsa Bt
      • Pécs, Ungarn, 7633
        • PsychoTech Kft
      • Szekszárd, Ungarn, 7100
        • Tolna Megyei Balassa Janos Korhaz

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 74 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Transferred-entry participants:

-Participants must have completed the double blind (DB) (expand DB) Treatment Phase of Study 67953964MDD3001 or Study 67953964MDD3002 without early treatment discontinuation or switch in the oral selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in the parent study

Direct-entry participants:

  • Have a Hamilton Depression Rating Scale (HDRS)-17 total score of 20 or higher at the first and second screening interviews and must not demonstrate a clinically significant improvement (that is, an improvement of more than 20 percent (%) on their HDRS-17 total score) between the first and the second independent HDRS-17 assessments
  • Have had an inadequate response to at least 1 oral antidepressant treatment, administered at an adequate dose (at or above the minimum therapeutic dose per Massachusetts general hospital antidepressant treatment response questionnaire [MGH ATRQ]) and duration (at least 6 weeks) in the current episode of depression
  • Must be an outpatient at open-label treatment phase baseline
  • Meet Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders-Clinical Trials Version (SCID-CT)

Direct-entry and Transferred-entry Participants:

-Participants should not take any prohibited medication or food supplements

Exclusion Criteria:

Transferred-entry Participants:

  • Participant has been non-compliant with the study intervention administration in the DB Treatment Phase in either of Studies 67953964MDD3001 or 67953964MDD3002 (that is, have missed either 4 or more consecutive doses of study intervention or a total of 8 or more doses during the DB Treatment Phase)
  • Participant has any condition or situation/circumstance for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol specified assessments

Direct-entry Participants:

  • Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
  • Has a history or evidence of clinically meaningful noncompliance with current antidepressant therapy
  • Known allergies, hypersensitivity, or intolerance to aticaprant or any of its excipients

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Aticaprant 10 mg

Participants will enter this study directly or after completing double-blind phase of studies 67953964MDD3001 or 67953964MDD3002 and will receive Aticaprant 10 milligrams (mg), once daily, orally in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy on Day 1 up to 52 weeks.

Aticaprant 10 mg tablet will be administered orally.

Andre navne:
  • JNJ-67953964

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Open Label (OL) Treatment Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and AEs of Special Interest (AESI)
Tidsramme: From start of open-label treatment (Day 1) up to Week 52

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as any AE occurring at or after the initial administration of study intervention through the end of OL treatment phase. TEAEs included both serious and non serious AEs. AESI was defined as adverse events that were considered to be of special interest in this study.

From start of open-label treatment (Day 1) up to Week 52
Follow-up Phase: Number of Participants With Adverse Events (AEs) and AEs of Special Interest (AESI)
Tidsramme: From Week 52 to Week 54

An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. AESI was defined as adverse events that were considered to be of special interest in this study.

From Week 52 to Week 54
Change From Baseline in Vital Sign Parameter: Blood Pressure (Systolic and Diastolic Blood Pressure)
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])

Change from baseline in vital sign parameter (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])
Change From Baseline in Vital Sign Parameter: Pulse Rate
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])

Change from baseline in vital sign parameter (pulse rate) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])
Change From Baseline in Vital Sign Parameter: Temperature
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])

Change from baseline in vital sign parameter (temperature) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])
Change From Baseline in Vital Sign Parameter: Weight
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])

Change from baseline in vital sign parameter (weight) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])
Change From Baseline in Body Mass Index (BMI)
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])

Change from baseline in BMI was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52), and Follow-up (OL) (up to 14 days after endpoint (OL) [maximum up to Week 54])
OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)
Tidsramme: Baseline (DB, Day 1) up to Endpoint (OL) (at any time between Week 4 to Week 52) (Up to Week 58 from DB baseline)

C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation(1-5), suicidal behavior(6-10). Total score ranged from 0 to 10. Higher scores=more severe suicidal ideation and behavior. Baseline=most recent assessment prior to first dose of study treatment in parent study (NCT05455684 and NCT05550532). Categories with at least 1 non-zero data values are reported.

Baseline (DB, Day 1) up to Endpoint (OL) (at any time between Week 4 to Week 52) (Up to Week 58 from DB baseline)
Follow-up Phase: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by C-SSRS
Tidsramme: Baseline (DB, Day 1), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52]) (maximum up to Week 54 from OL baseline and Week 60 from DB baseline)

C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation(1-5), suicidal behavior(6-10). Total score ranged from 0 to 10. Higher scores=more severe suicidal ideation and behavior. Baseline=most recent assessment prior to first dose of study treatment in parent study (NCT05455684 and NCT05550532). Categories with at least 1 non-zero data values are reported.

Baseline (DB, Day 1), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52]) (maximum up to Week 54 from OL baseline and Week 60 from DB baseline)
OL Treatment Phase: Change From Baseline in Laboratory Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameters (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatine kinase, gamma glutamyl transferase) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameters: Albumin, Protein, Erythrocyte (Ery.) Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameters (albumin, protein, Ery. mean corpuscular HGB concentration, hemoglobin) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, HDL Cholesterol, LDL Cholesterol, Magnesium, Phosphate, Potassium, Sodium, Triglycerides, Urea Nitrogen
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameters (bicarbonate, calcium, chloride, cholesterol, glucose, HDL cholesterol, LDL cholesterol, magnesium, phosphate, potassium, sodium, triglycerides, urea nitrogen) was reported. Baseline (OL) was defined as the assessment taken on or prior to this first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameters: Bilirubin, Creatinine, Direct Bilirubin, Indirect Bilirubin, Urate
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameters (bilirubin, creatinine, direct bilirubin, indirect bilirubin, urate) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, Leukocytes
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameters (basophils, eosinophils, lymphocytes, monocytes, platelets, leukocytes) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Ery. Mean Corpuscular Hemoglobin (MCH)
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameter (Ery. MCH) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Ery. Mean Corpuscular Volume (MCV)
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameter (Ery. MCV) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Hematocrit
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameter (hematocrit) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Specific Gravity
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameter (specific gravity) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Urine pH
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameter (urine pH) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Hyaline Casts
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameter (hyaline casts) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in Laboratory Parameter: Squamous Epithelial Cells, Transitional Epithelial Cells, Tubular Epithelial Cells, Urine Erythrocytes, Urine Leukocytes
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in laboratory parameters (squamous epithelial cells, transitional epithelial cells, tubular epithelial cells, urine erythrocytes, urine leukocytes) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in the OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, RR Interval, QTcB Interval, QTcF Interval
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)

Change from baseline in ECG parameters (PR interval, QRS duration, QT interval, RR interval, QTcB interval, QTcF interval) was reported. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52)
OL Treatment Phase: Number of Participants With Withdrawal Symptoms as Assessed by Physician Withdrawal Checklist 20-item (PWC-20)
Tidsramme: Endpoint (OL) (at any time between Day 2 to Week 52)

Number of participants with withdrawal symptoms as assessed by PWC-20 was reported. PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. Items were as follows: loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesias, difficulty concentrating-remember, depersonalization-derealization. Each item score ranges from 0 (not present)-3 (severe), where 0=not present, 1=mild, 2=moderate, 3=severe. Higher scores indicated more affected condition.

Endpoint (OL) (at any time between Day 2 to Week 52)
Follow-up Phase: Number of Participants With Withdrawal Symptoms as Assessed by Physician Withdrawal Checklist 20-item (PWC-20)
Tidsramme: Follow-up (up to 14 days after endpoint (OL) [at any time between Day 2 to Week 52 {maximum up to Week 54}])

Number of participants with withdrawal symptoms as assessed by PWC-20 was reported. PWC-20 was a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. Items were as follows: loss of appetite, nausea-vomiting, diarrhea, anxiety-nervousness, irritability, dysphoric mood-depression, insomnia, fatigue, poor coordination, restlessness, diaphoresis, tremor, dizziness, headaches, muscle aches or stiffness, weakness, increased acuity sound smell touch, paresthesias, difficulty concentrating-remember, depersonalization-derealization. Each item score ranges from 0 (not present)-3 (severe), where 0=not present, 1=mild, 2=moderate, 3=severe. Higher scores indicated more affected condition.

Follow-up (up to 14 days after endpoint (OL) [at any time between Day 2 to Week 52 {maximum up to Week 54}])
OL Treatment Phase: Percentage of Participants With Clinically Relevant Sexual Dysfunction Over Time as Determined by Arizona Sexual Experiences Scale (ASEX)
Tidsramme: Endpoint (OL) (at any time between Week 12 to Week 52)

The ASEX was a patient-reported 5-item rating scale, which was used to quantify sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items was rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction. Sexual dysfunction was defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items.

Endpoint (OL) (at any time between Week 12 to Week 52)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])

The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score is the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition. Negative change in MADRS total score indicated improvement. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])
Change From Baseline in Patient Health Questionnaire, 9-item (PHQ-9) Total Score
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 12 to Week 52 {maximum up to Week 54}])

Change from baseline in PHQ-9 total score was reported. The PHQ-9 was a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) MDD criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 was categorized as follows: none-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). Negative changes in PHQ-9 total score indicated improvement. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 12 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 12 to Week 52 {maximum up to Week 54}])
Change From Baseline in Dimensional Anhedonia Rating Scale (DARS) Total Score
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])

Change from baseline in DARS total score was reported. The DARS was a 17-item self-report questionnaire that is designed to assess anhedonia in MDD across the 4 domains: hobbies, social activities, food/drink, and sensory experience. The DARS scale measures desire, motivation, effort, and consummatory pleasure. The DARS was rated on a 5-point Likert scale (0=not at all, 1=slightly, 2=moderately, 3=mostly, 4=very much) and responses were summed to generate the total score (ranges from 0 to 68). A lower total score was indicative of greater anhedonia. Positive changes in DARS total score indicated improvement. Baseline (OL) was defined as the assessment taken on or prior to the first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score
Tidsramme: Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])

CGI-S provides an overall clinician-determined summary measure of severity of participant's illness that takes into account all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S 7-point scale was a global assessment that measures the clinician's impression of severity of illness of the participant. CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Higher score=more severe illness. Negative changes in CGI-S score indicated improvement. Baseline (OL)=assessment taken on or prior to first dose of study intervention in this OL study.

Baseline (OL, Day 1), Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in the MADRS Total Score
Tidsramme: At Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])

Percentage of participants with >=50% reduction from baseline in MADRS total score was reported. A participant was defined as responder at a given time point if percent improvement from baseline in MADRS total score was >=50% at that time point. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. Scale consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was sum of scores from individual question items, which ranged from 0 to 60; higher scores=more severe condition. Negative change in MADRS total score = improvement. Baseline=most recent assessment prior to first dose of study treatment in parent study (NCT05455684 and NCT05550532).

At Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (OL) (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])
Percentage of Participants With Remission of Depressive Symptoms
Tidsramme: At Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])

Percentage of participants with remission of depressive symptoms was reported. A participant was defined as remitter at a given time point if the MADRS total score less than or equal to (<=) 10 at that time point. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranges from 0 to 60; higher scores represent a more severe condition. Negative change in MADRS total score indicated improvement.

At Endpoint (OL) (at any time between Week 4 to Week 52), and Follow-up (up to 14 days after endpoint [OL] [at any time between Week 4 to Week 52 {maximum up to Week 54}])

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. september 2022

Primær færdiggørelse (Faktiske)

25. april 2025

Studieafslutning (Faktiske)

8. maj 2025

Datoer for studieregistrering

Først indsendt

25. august 2022

Først indsendt, der opfyldte QC-kriterier

25. august 2022

Først opslået (Faktiske)

26. august 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CR109218
  • 2022-000430-42 (EudraCT nummer)
  • 67953964MDD3003 (Anden identifikator: Janssen Research & Development, LLC)
  • 2023-508163-74-00 (Registry Identifier: EUCT number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner